Philippe Berthon

Blue Bees Therapeutics is a biotech company funded early 2022, which aims to develop new immunotherapies against cancer based on a breakthrough technology, to generate a series of proteins / MAbs potentiating the anti-tumor immune response. We are currently validating a first drug candidate whose development is supported by SATT Paris-Saclay. Blue Bees Therapeutics is a CEA Spin-off from the Paris-Saclay Joliot Curie Institute.

DNA finance team is experts in investments and value creation in the healthcare industry. We leverage our Bioteh Promise investment fund expertise and capabilities to create value through our deep understanding of the biotech and medtech ecosystem. DNA Finance offers strategic consulting and value generation advisory to healthcare companies, including fund raising.

Culture Top was an in vitro diagnostics (IVD) company in infectious disease, co-founded in 2015 by Eurobio Scientific [Euronext: ALERS.PA] and the IHU Méditerranée Infection (Marseille). During our mandate as CEO, we have structured a private equity financing of 3M€, secured the sale of the company to Eurofins [Euronext: ERF.PA], managed Eurobio Scientific exit.

The CC2V is a local authority regrouping 15 municipalities, including Soisy-sur-Ecole. As elected VP, we were in charge of business development. Our main responsibility was the commercialization of an industrial and commercial park of 35 ha, with 75 companies and 500 jobs created or installed during our mandate

Soisy-sur-Ecole is a small town located south of Essonne, Ile-de-France. As mayor, we oversee all departments, including finance, education, town planning and housing, roads and transportation, development and security, with the support of a 15-person city council and the city staff. Philippe Berthon has been a member of the city council since 2008, until 2020, and resigned in May 2020.

Tridek-One is a biotechnology company developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. We have raised 3M€ in mid-2019, supported by two venture funds, AdBio Partners (Fr) and Advent Life Sciences (UK).

Aurgalys, was a corporate advisory firm specialized in life sciences and healthcare. Aurgalys has been acquired by Genesta Finance in june 2018 to create a group able to cover all technology sectors. Former Aurgalys team members brought their life sciences and healthcare expertise in the new entity. Aurgalys proposed a full range of services that suits fast growing/ life science & healthcare companies and investor needs: Corporate Finance & Fund Raising, IPO (CIF & Listing Sponsor Euronext), Independant Valuation, Equity Research (SFAF registered), Investor relations, Interim Management, Company / Investor Assistance and consulting, Due Diligence, Business Development. Some disclosed customers: BioAlliance/ Onxeo, DNA Therapeutics, Global BioEnergies, Diaxonhit/ Eurobio Scientific, Génopole, Cellectis, Evolva, MyoPowers, Sensorion, Abivax, Ose Immuno, BioCorp, Noxxon Pharma, Intrasense, Implanet, Medial Lab, Parx Plastics, ...

French Association for Biotechnology: France Biotech mission is to contribute to position France and Europe as leaders in the healthtech industry. Philippe set up the France Biotech - Corporate Finance Committee and chaired it until 2011.

BioPharmaceutical company which develops immuno-therapeutics to treat cancer. Most advanced compounds Vx-001 was currently in phase IIb/III in lung cancer (NSCLC). Philippe managed the company restructuring, private equity financing for 7M€, launch of VX-001 clinical trials and stratégic partnering with Celgene.

Founded UroGene in March 1998, as a spin-off of my University Paris VII lab (Upres 3104/ CeRePP). Biotechnology/BioPharmaceutical company dedicated to urological cancer. We raised >25M€ and developed a preclinical and clinical portfolio up to phase II. Urogene was sold to group Pierre Fabre early 2005.